$LLY

Jonsson Patrik sold $7.6M of LLY

Jonsson Patrik (EVP & President, LLY Int'l) sold 6,500 shares of ELI LILLY & Co (LLY) at $1175.10 ($7.64M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jonsson Patrik
Published Aug 18, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings; it does not include guidance, trial results, regulatory actions, or deal terms.

02

Market read

Traders may note insider selling, but the 10b5-1 framing and lack of fundamental updates make it low-signal for price action.

03

What to watch

The disclosure does not indicate whether sales were part of broader diversification, tax planning, or option exercises, limiting inference beyond the fact of selling.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Eli Lilly & Co.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows EVP and President Jonsson sold 6,500 shares at $1,175.10 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an open-market sale by an insider, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, unusually large or clustered insider selling can be interpreted as private caution, though this article provides no comparative context.

Key entities

  • ELI LILLY & Co

    Subject of the Form 4 insider sale by EVP and President, LLY International, Patrik Jonsson.

  • Patrik Jonsson

    EVP and President, LLY International, reported an open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYHighAI 9/10

Eli Lilly (LLY) Stock Fair Value Edges Higher As Analysts Back GLP 1 Growth

Eli Lilly (LLY) received FDA approval for Inluriyo's combination therapy, boosting its breast cancer treatment options. Analysts at Berenberg upgraded LLY, citing growth prospects in weight-loss drugs and a robust pipeline. The company's fair value estimate increased to $1,325.39, with slight adjustments to revenue growth and net profit margin. Novartis' failed Lp(a) drug trial may impact similar programs at LLY and Amgen.

$LLYHighAI 9/10

Inluriyo Plus Verzenio Wins Full FDA Approval for ESR1 Mutated Advanced Breast Cancer After Progression on Endocrine Therapy

The FDA granted full approval to Eli Lilly's imlunestrant (Inluriyo) combined with abemaciclib (Verzenio) for treating ESR1-mutated advanced breast cancer post-endocrine therapy. Approval based on EMBER-3 trial showing median progression-free survival of 11.1 months for the combination vs. 5.5 months for imlunestrant alone in 159 patients. Guardant360 CDx assay approved as companion diagnostic. Common side effects include diarrhea and reduced neutrophil counts.

$TWSTMed

TWST Surges As Twist Bioscience Wins Eli Lilly AI Deal

Twist Bioscience (TWST) stock rose 7.1% after securing an AI deal with Eli Lilly. The company reported $377M revenue, 52% gross margin, and -31.8% EBIT margin. Analysts highlight its AI-driven drug discovery capabilities but note persistent losses and rich valuation at 24x sales. Technical analysis suggests strong bullish momentum with support at $155.

$LLYHighAI 9/10

Health: US FDA approves Lilly's breast cancer drug combo

The US FDA approved Eli Lilly's Inluriyo-Verzenio combo for treating advanced breast cancer with ESR1 mutations. The approval follows a study showing 11.1 months of progression-free survival vs. 5.5 months with Inluriyo alone. The combo is for ER-positive, HER2-negative patients who progressed after hormone therapy.

$LLYMedAI 8/10

Eli Lilly’s Leading Position in the Weight-Loss Drug Market Remains Solid, Competition Landscape for Oral Drugs Begins to Emerge

Eli Lilly (LLY) maintains a strong position in the weight-loss drug market. Its oral GLP-1 drug, Foundayo, is gaining on Novo Nordisk's (NVO) Wegovy pill, with the prescription gap narrowing. Foundayo's convenience may drive adoption, though patient switching could slow progress. Additionally, Eli Lilly's selpercatinib tablets were approved in China, expanding its product pipeline. Analysts expect the weight-loss drug market to reach $100 billion by 2030.

$LLYHighAI 9/10

FDA Grants Full Approval To Lilly's Inluriyo Plus Verzenio For ESR1-Mutated Breast Cancer

Eli Lilly (LLY) received FDA full approval for Inluriyo in combination with Verzenio to treat ESR1-mutated breast cancer. The treatment is for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. LLY shares closed at $1,152.93 on Friday. Inluriyo is also in Phase 3 trials for early-stage breast cancer, with results expected in 2027.